The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.
Continue reading →
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
Continue reading →
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
Continue reading →
While the state wants to direct cost savings to priority areas, some have concerns about the waivers’ impacts on vulnerable student populations.
Continue reading →